Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood is ...

While taking testosterone-based HRT, your doctor will monitor your bloodwork for signs of polycythemia. If found, several treatment options are available. Testosterone is responsible for many body ...

Polycythemia vera (PV) is a rare disorder that affects blood cell and platelet production. The early stages of polycythemia vera often cause nonspecific symptoms, but advanced stages can lead to ...

Persistent polycythemia, even if mild, should prompt investigations for secondary causes and, if none are found, referral to hematology and JAK2 mutation testing for polycythemia vera.

Polycythemia is an increase of red blood cells in the body. The extra cells cause the blood to be thicker, and this, in turn, increases the risk of other health issues, such as blood clots.

Secondary polycythemia is the overproduction of red blood cells. It causes your blood to thicken, which increases the risk of a stroke. It’s a rare condition. The primary function of your red blood ...

Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...